Evidence map›Paper›PMID 33806405›Full record

ArticlePharmaceutics2021

In Silico and In Vitro Tailoring of a Chitosan Nanoformulation of a Human Metabolic Enzyme.

Paulo R Lino, João Leandro, Mariana Amaro, Lídia M D Gonçalves, Paula Leandro, António J Almeida

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Paulo R LinoFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
João LeandroFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
Mariana AmaroFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
Lídia M D GonçalvesFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-6799-2740
Paula LeandroFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-7807-4726
António J AlmeidaFaculty of Pharmacy, Research Institute for Medicines, Universidade de Lisboa, 1649-003 Lisboa, Portugal.ORCID 0000-0002-2946-9342
University of Lisbon · PT

Funding

Fundação para a Ciência e a Tecnologia UIDB/04138/2020; UIDP/04138/2020; PTDC/QUI/64023/2006; PTDC/EBB-BIO/101237/2008; SFRH/BSAB/1210/2011; SFRH/BD/47946/2008National PKU Alliance Human phenylalanine hydroxylase and nanobiomaterials: a novel enzyme reposition therapy approach to PKU
6 · The paper itself

Abstract

Enzyme nanoencapsulation holds an enormous potential to develop new therapeutic approaches to a large set of human pathologies including cancer, infectious diseases and inherited metabolic disorders. However, enzyme formulation has been limited by the need to maintain the catalytic function, which is governed by protein conformation. Herein we report the rational design of a delivery system based on chitosan for effective encapsulation of a functionally and structurally complex human metabolic enzyme through ionic gelation with tripolyphosphate. The rationale was to use a mild methodology to entrap the multimeric multidomain 200 kDa human phenylalanine hydroxylase (hPAH) in a polyol-like matrix that would allow an efficient maintenance of protein structure and function, avoiding formulation stress conditions. Through an in silico and in vitro based development, the particulate system was optimized with modulation of nanomaterials protonation status, polymer, counterion and protein ratios, taking into account particle size, polydispersity index, surface charge, particle yield production, protein free energy of folding, electrostatic surface potential, charge, encapsulation efficiency, loading capacity and transmission electron microscopy morphology. Evaluation of the thermal stability, substrate binding profile, relative enzymatic activity, and substrate activation ratio of the encapsulated hPAH suggests that the formulation procedure does not affect protein stability, allowing an effective maintenance of hPAH biological function. Hence, this study provides an important framework for an enzyme formulation process.

Indexed as

chitosanenzyme therapeuticshuman phenylalanine hydroxylasemolecular modellingnanoencapsulationself-assembly

Identifiers

PMID33806405
PMCPMC8000282
OpenAlexW3135401823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.